Tacrolimus - Jina Pharmaceuticals/Intas Pharmaceuticals

Drug Profile

Tacrolimus - Jina Pharmaceuticals/Intas Pharmaceuticals

Alternative Names: Nanosomal tacrolimus; Tacrolimus liposomal

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Class Lactones; Macrolides
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Transplant rejection
  • Phase II Rheumatoid arthritis
  • Clinical Phase Unknown Atopic dermatitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Transplant-rejection in Unknown (PO)
  • 30 Aug 2016 Intas Pharmaceuticals and Jina Pharmaceuticals plans a phase II trial for Lichen planus (CTRI2015-09-006211)
  • 16 Aug 2016 Intas Pharmaceutical plans a clinical bioequivalence trial for Atopic dermatitis in India (Topical) (CTRI2016-03-006735)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top